

NOTE

BIOSYNTHETIC PREPARATION OF THE TRITIUM LABELLED 3 α -HYDROXY-5 α -PREGNAN-20-ONE, AN ALLOSTERIC MODULATOR OF GABAERGIC NEUROTRANSMISSION

Astrid Jussofie,^a Ibrahim Jussofie,^b Martin Stoppok,^a E. Rodney Lax^a

^aInstitut für Physiologische Chemie des Universitätsklinikums Essen, Hufelandstraße 55, 4300 Essen 1; ^bTh. Goldschmidt AG Essen, Goldschmidtstraße 100, 4300 Essen 1

Corresponding author: Astrid Jussofie
Universitätsklinikum Essen
Institut für Physiologische Chemie
Hufelandstr. 55
4300 Essen 1
telephone: 0201/723-4105
telefax: 0201/723-4694

SUMMARY

A procedure for the biosynthetic preparation of 3 α -hydroxy-5 α -[1,2,6,7-³H]-pregnan-20-one (³H-HPO) with high specific activity convenient for binding studies was developed. ³H-HPO was synthesized from [1,2,6,7-³H]progesterone using a microsomal preparation from rat liver and NADPH. The progesterone metabolite was purified by silica gel 60 and Sephadex LH 20 chromatography. The identity of the product was confirmed by reverse isotopic dilution of chemically synthesized and highly purified 3 α -hydroxy-5 α -pregnan-20-one. The yield for radiolabelled HPO was 60% and its purity was > 98%.

Keywords: 3 α -hydroxy-[1,2,6,7-³H]-pregnan-20-one; biosynthetic preparation; progesterone; steroids

INTRODUCTION

The GABA_A-receptor has besides the binding site for GABA at least three allosteric, pharmacologically identified binding sites. The effect of allosteric modulators of this receptor were commonly studied by determining alterations in the binding of ³H-muscimol to GABA_A-receptor sites. Among the various modulators 3 α -hydroxy-5 α -pregnan-20-one (HPO), a metabolite of progesterone, has been suggested as an endogenous candidate mediating sex steroid effects on neurotransmission. To study the allosteric binding site for

HPO *in vitro*, a highly purified tritium labelled ligand is necessary. This paper describes the biosynthetic preparation starting from commercially available tritium labelled progesterone. HPO (3) is formed from progesterone (1) via 5 α -pregnenedione (2) by two metabolizing enzymes, 5 α -reductase and 3 α -hydroxysteroidoxidoreductase, in various mammalian tissues (Fig. 1).




Fig. 1:

Biosynthetic formation of 3 α -hydroxy-5 α -pregnan-20-one (HPO) by 5 α -reduction of progesterone and subsequent reversible 3 α -reduction of 5 α -dihydroprogesterone

MATERIAL AND METHODS

[1,2,6,7- ^3H]-progesterone was purchased from Amersham-Buchler (Braunschweig, GER). The used buffer comprised 15 mM Tris-HCl, 8.7% glycerol and 10 mM monothioglycerol (= TGT-buffer, pH 7.4).

Biopreparation of 3 α -hydroxy-5 α -[1,2,6,7- ^3H]pregnan-20-one (^3H -HPO). ^3H -HPO was synthesized from [1,2,6,7- ^3H]progesterone with the aid of liver microsomes (preparation see next paragraph) in the presence of NADPH. 50 nmol NADPH and 2 nmol ^3H -progesterone, each dissolved in 1 ml TGT-buffer, were added to 5 ml of liver microsomes equivalent to 200 mg liver suspended in TGT-buffer. After incubation at 37°C for 60 min the reaction was stopped by adding 1 ml of ice-cold double distilled water. The steroids were then extracted with dichloromethane and subjected to chromatography on a silica gel 60 (Merck, Darmstadt, GER) column (230-400 mesh, length 20 cm, ID 1cm) with dichloromethane/acetone (10:1 v/v) as eluent system. Further purification of the ^3H -HPO was performed on a Sephadex-LH 20 (LKB-Pharmacia, Freiburg i. BRSG., GER) column (length 20 cm, ID 1 cm) with ethanol as eluent. Aliquots of the incubation assay as well as purified product were chromatographed on thin layer silica gel plates (Merck, Silica gel F₂₅₄) in the system dichloromethane/acetone (10:1 v/v).

Liver microsomes were prepared from rat (strain Han: SPRD, Zentralinstitut für Versuchstierzucht, Hannover, GER) livers that were perfused with physiological saline before homogenization of the tissue (TGT-buffer). A 25% (w/v) homogenate was made in TGT-buffer using a motor driven teflon glass homogenizer at 800 rpm. The homogenate was centrifuged at 10,000 g for 20 min (4°C) and the supernatant spun at 100,000g for 60 min. The resulting pellet, equivalent to 200 mg liver, was washed, centrifuged as described above, resuspended in 5 ml TGT-buffer and frozen at -190°C till use for enzymatic formation of ³H-HPO not later than 60 days.

A reference sample of inactive HPO was prepared essentially according to (2).

RESULTS AND DISCUSSION

1. Biopreparation of 3 α -hydroxy-5 α -[1,2,6,7-³H]pregnan-20-one

It was the aim of the present study to obtain highly pure, tritium labelled 3 α -hydroxy-5 α -pregnan-20-one by stereoselective 3 α - and 5 α - hydrogenation of [1,2,6,7-³H]progesterone. Monitoring the reaction course by TLC indicated that two parameters were critical: The ratio NADPH/substrate and incubation time. Under the conditions described here, the yield was 60% for 3 α -hydroxy-5 α -pregnan-20-one, which was the result of a compromise between the maximal extent of the hydrogenation of [1,2,6,7-³H]progesterone and minimal transformation of [³H]-HPO to more polar compounds.

A reference sample of inactive HPO was prepared essentially according to (2).

2. Identity of biosynthetically prepared tritium labelled 3 α -hydroxy-5 α -pregnan-20-one with the chemically synthesized compound.

A mixture of biosynthetically prepared 3 α -hydroxy-5 α -[1,2,6,7-³H]pregnan-20-one with chemically synthesized HPO, crystallized from different solvents, exhibited constant specific activity (Tab. 1), indicating the identity of the radioactive compounds with the radioinert HPO.

Table 1. Reverse isotopic dilution of 3 α -hydroxy-5 α -pregnan-20-one

<u>solvent</u>	<u>dpm/mg</u>
cyclohexane	2866.7 \pm 182.5
acetone	2916.6 \pm 113.6
ethyl acetate	2829.1 \pm 49.8

HPO was mixed with the putative ^3H -HPO in order to provide a specific activity of 100 Bq/mg.

The final radiopurity of ^3H -HPO was > 98%.

ACKNOWLEDGMENTS

The excellent technical assistance of Mrs. Edelgard Heimeshoff is gratefully appreciated. Professor Dr. Herbert Schriefers is thanked for critical discussion of the manuscript.

REFERENCES

1. Doddrell, D.M., Pegg, D.T. and Bendall, M.R. - J. MAGN. RESON. 48: 323 (1982).
2. Wiebe, J.P., Decline, C. and Bucklingham, K.D. - STEROIDS 45: 39 (1985)